Quantum-Si incorporated
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeffrey Alan Hawkins
- Full Time Employees
- 145
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 29 Business Park Drive Branford CT United States of America 06405
- IPO Date
- Nov 13, 2020
- CIK
- 0001816431
- Website
- quantum-si.com
- Similar Companies
- Business
- Quantum-Si Incorporated develops and commercializes advanced protein sequencing technologies through its proprietary single-molecule detection platform. Its core products include the Platinum and Platinum Pro Next-Generation Protein Sequencers™, which enable single-molecule, single-amino-acid resolution sequencing for research use. The company also offers consumables such as library preparation kits, barcoding kits, sequencing kits, and the Platinum Analysis Software, a cloud-based solution that automates data workflows and provides comprehensive visualization for protein analysis. These products support applications in antibody characterization, biomarker identification, protein variant detection, protein barcoding, and post-translational modification analysis. Quantum-Si serves research laboratories and biopharmaceutical companies globally from its headquarters in Branford, Connecticut, and operates within the life sciences and proteomics industry. Recent major developments include the global launch and shipping of the Platinum Pro sequencer in early 2025, featuring enhanced user interfaces, cloud and on-instrument data analysis, and a Pro Mode for custom applications. In 2024, the company introduced new consumables such as the v2 Library Preparation Kit and a new Barcoding Kit, with the v4 Sequencing Kit scheduled for launch in the third quarter of 2025. Quantum-Si is developing a next-generation proteomics platform named Proteus, targeting a mid-2026 launch. Proteus promises ultrasensitive proteoform detection, rapid sequencing chemistry reducing run time to 90 minutes or less, and automated liquid handling to boost sample throughput. The company has expanded strategic collaborations, including a partnership with Planet Innovation for development and manufacturing of the Proteus platform and a collaboration with SkyWater Technology to advance chip production for these platforms. In September 2025, Quantum-Si entered a sales agreement to offer up to $100 million of Class A common stock to strengthen its financial flexibility. Founded in 2013, Quantum-Si integrates biology, chemistry, and artificial intelligence to advance proteomics beyond traditional methods, aiming to revolutionize drug discovery and diagnostics. It operates primarily in the United States, serving the global research and biopharmaceutical communities. Its strategic product evolution and partnerships position Quantum-Si as a pioneer in delivering accessible, high-resolution protein sequencing solutions. This description consolidates Quantum-Si’s core products, recent technological advancements, strategic partnerships, and financial activities through 2024 and 2025.
Company News
Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript
Quantum-Si Q2 Earnings Call Highlights
Quantum-Si Incorporated (QSI) Reports Q2 Loss, Tops Revenue Estimates
Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update
Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™
Quantum-Si Announces the Expansion of the Proteus™ Roadshow
Quantum-Si Announces the Expansion of the Proteus™ Roadshow
euNetworks launches new quantum-safe private connectivity service powered by Adtran's encrypted optical transport technology
Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Q1 Earnings Call Highlights
Quantum-Si Incorporated (QSI) Reports Q1 Loss, Misses Revenue Estimates
Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones
Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard